At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIIB, Single Arm Study, of Durvalumab in Combination With Platinum-Etoposide for Untreated Patients With Extensive-Stage Small Cell Lung Cancer Reflecting Real World Clinical Practice in Spain (CANTABRICO).
In Brief
A Phase 3 clinical trial evaluating Durvalumab, Cisplatin, and 2 other interventions for Small Cell Lung Carcinoma Extensive Disease. Completed, enrolled 101 participants across 34 sites.
Detailed Summary
This is a Phase IIIb, interventional, single arm, multicentre study to evaluate safety, effectivenees, use of resources and patient reporting outcomes in patients with ES-SCLC treated with durvalumab in combination with platinum-etoposide as first-line treatment in Spain.
Study Details
Timeline
Interventions
Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.
Cisplatin as an IV infusion per local standards (usually over 60 to 120 minutes on Day 1) of each cycle.
Etoposide sequentially administered per local standards (usually over 30 to 60 minutes IV infusion) on Days 1, 2, and 3 of each cycle.
Carboplatin as an IV infusion per local standards (usually over 30 to 60 minutes on Day 1) of each cycle.